市场调查报告书
商品编码
1492689
可待因市场:按配方、等级、应用、分销管道和最终用户划分 - 2024-2030 年全球预测Codeine Market by Formulation (Capsule, Syrup, Tablet), Grade (Laboratory Grade, Pharmaceutical Grade), Application, Distribution Channel, End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年可待因市场规模为39.3亿美元,预计2024年将达41.1亿美元,2030年将达到54亿美元,复合年增长率为4.65%。
可待因是一种鸦片类药物和氢可酮的前驱药物。它被添加到各种药物中,例如锭剂和糖浆,或与其他药物组合使用。与慢性疼痛相关的慢性疾病的增加增加了对可待因等有效镇痛药物的需求。老年人口的增加和医疗基础设施的持续扩张正在推动市场成长,特别是在新兴经济体。然而,由于可待因可能被滥用,且持续的全球鸦片危机导致含可待因的鸦片类药物处方量减少,严格的监管阻碍了市场扩张。不断增加的研发活动旨在开发可维持治疗功效的防滥用製剂,预计将为市场成长创造机会。人们越来越多地寻求新型药物输送系统,例如针对个人遗传特征的缓释性胶囊和精准医疗方法,正在扩大市场基础。
主要市场统计 | |
---|---|
基准年[2023] | 39.3亿美元 |
预测年份 [2024] | 41.1亿美元 |
预测年份 [2030] | 54亿美元 |
复合年增长率(%) | 4.65% |
区域洞察
美国和加拿大拥有强大的製药业,促进可待因治疗药物的生产和分销。此外,研究和开发工作正在进行中,以创新含有可待因的疼痛管理疗法,预计这将成为美洲市场成长的基础。南美国家,特别是巴西和阿根廷,对可待因的取得宽鬆且监管严格,以适应不同的医疗保健能力和经济状况。在欧洲,可待因被广泛用于监管良好的疼痛管理通讯协定中,特别是在西欧。在中东,对含有可待因和其他药物的疼痛管理解决方案的需求不断增长。然而,中东地区的监管机构对提供处方可待因实施了严格的规定,以避免滥用可待因。在非洲,正在製定法律规范以促进阿片类药物(包括可待因)的医疗应用,从而促进市场成长。在亚太地区,中国、日本、印度和澳洲等国家实施了严格的法规来遏制可待因的滥用,强调处方通讯协定和预防性公共卫生宣传活动。此外,扩大医疗基础设施和提高对慢性疼痛的认识正在推动该地区的市场成长。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在可待因市场中的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对可待因市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并制定有效的策略来提高其市场竞争力。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对可待因市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[185 Pages Report] The Codeine Market size was estimated at USD 3.93 billion in 2023 and expected to reach USD 4.11 billion in 2024, at a CAGR 4.65% to reach USD 5.40 billion by 2030.
Codeine, an opioid and prodrug of morphine, is utilized for its analgesic, antitussive, and antidiarrheal effects. It is formulated into various medications, such as tablets and syrups, or combined with other medicines. Increasing the prevalence of chronic diseases with often chronic pain is elevating the need for effective analgesics identical to codeine. An increasing geriatric population and continuous expansion of the healthcare infrastructure, particularly in developing economies, drive market growth. However, the market expansion is hindered by stringent regulations owing to codeine's potential for abuse and the ongoing global opioid crisis, which has led to a decline in opioid prescriptions, including those for codeine. Rising research & development activities for developing abuse-deterrent formulations that maintain therapeutic efficacy are expected to create opportunities for market growth. The rising exploration of novel drug delivery systems, including extended-release capsules and precision medicine approaches tailored to individuals' genetic profiles, is expanding the market scope.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.93 billion |
Estimated Year [2024] | USD 4.11 billion |
Forecast Year [2030] | USD 5.40 billion |
CAGR (%) | 4.65% |
Regional Insights
In the Americas, the United States and Canada have robust pharmaceutical industries that facilitate the production and distribution of codeine medication. Moreover, ongoing research and development efforts for innovations in pain management therapies, including codeine, are expected to create a platform for market growth in the Americas. While in South American countries, specifically Brazil and Argentina, feature moderate accessibility to codeine under vigilant regulations, addressing varying healthcare capacities and economic conditions. In Europe, codeine is widely used within well-regulated pain management protocols, particularly in Western Europe. In the Middle East, there is an increase in the need for pain management solutions, including codeine with other medications. However, the regulatory authorities in the region enforce strict regulations to provide the prescribed codeine medication to avoid misuse of codeine in the Middle East region. In Africa, ongoing development in regulatory framework has boosted the healthcare application of an opioid class of medication, including codeine, contributing to market growth. In Asia Pacific, countries such as China, Japan, India, and Australia enforce stringent regulations to curb codeine misuse, emphasizing prescription protocols and preventive public health campaigns. Moreover, expanding healthcare infrastructure and improving awareness about chronic pain conditions drive market growth in the region.
Market Insights
The market dynamics represent an ever-changing landscape of the Codeine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Codeine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Codeine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Advancements in Developing Enhanced Pain Relief Medications
Researchers at UNC Health have made significant strides in perfecting pain relief medications, focusing expressly on minimizing side effects associated with opioid use. This latest study emphasized designing drugs that provide effective pain management while substantially reducing the potential for addiction and other serious side effects such as respiratory depression. The scientists employed advanced molecular technology to understand better opioid receptors' behavior, which has led to the creation of molecules that target pain pathways more precisely. This breakthrough could revolutionize how pain is managed, offering relief to patients with chronic and acute pain conditions and potentially curtailing the opioid crisis by providing safer alternatives. [Published On: 2023-01-12]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Codeine Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Codeine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accord Healthcare by Intas Pharmaceuticals, Advik Pharma, AstraEureka Pharmaceuticals, Bristol Laboratories Limited, Crescent Pharma Limited, Johnson Matthey Plc, Noramco, Inc., Omnica Laboratories, Pfizer Inc., Professional Compounding Centers of America, Inc., SANOFI WINTHROP INDUSTRIE, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage